Indie Asset Partners, LLC Crispr Therapeutics Ag Transaction History

Indie Asset Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$70.09 - $111.29 $204,312 - $324,410	-2,915 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$110.2 - $156.64 $66,671 - $94,767	-605 Reduced 17.19%	2,915 $326,000
Q2 2021 Aug 11, 2021	SELL	$100.84 - $161.89 $50,117 - $80,459	-497 Reduced 12.37%	3,520 $570,000
Q1 2021 May 13, 2021	BUY	$110.72 - $210.04 $53,145 - $100,819	480 Added 13.57%	4,017 $489,000
Q4 2020 Feb 09, 2021	BUY	$79.67 - $173.23 $43,181 - $93,890	542 Added 18.1%	3,537 $542,000

Q3 2020 Nov 13, 2020	BUY	$78.5 - $100.64 $235,107 - $301,416	2,995 New	2,995 $251,000

549

56.3M

2.91M

2.47M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.14B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Indie Asset Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Indie Asset Partners, LLC with notifications on news.